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Introduction
Current serum prostate-specific antigen (PSA)-based screening practices cannot reliably 
distinguish between men with indolent disease versus those with life-threatening disease. In 
this regard, PSA-based screening has been associated with an “over-diagnosis” of prostate 
cancer (PC), with some men possibly being diagnosed and treated for a seemingly indolent 
tumor that may never have been detected nor caused symptoms (Andriole et al. 2009; 
Schroder et al. 2009). Accordingly, there is an urgent need for new biomarkers that can 
better differentiate tumor behavior and clinical outcome.
Genome-wide association studies (GWAS) of PC patients and controls have identified 
approximately 100 different single nucleotide polymorphisms (SNPs) associated with the 
overall risk of being diagnosed with PC (Al Olama et al. 2014; Amundadottir et al. 2006; 
Choudhury et al. 2012; Eeles et al. 2008b; Eeles et al. 2013; Gudmundsson et al. 2009; 
Gudmundsson et al. 2007a; Gudmundsson et al. 2008; Gudmundsson et al. 2007b; Haiman 
et al. 2007; Thomas et al. 2008; Yeager et al. 2007). Most of these initial discovery studies 
have compared men with non-aggressive or moderately-aggressive tumors to controls 
without known PC. Although some of these studies have been performed or validated in 
different racial populations (Cook et al. 2014; Freedman et al. 2006; Haiman et al. 2011; 
Han et al. 2014; Wang et al. 2012; Zheng et al. 2010), the great majority have been limited 
to men of European ancestry (Ishak and Giri 2011). Thus, while the results advance the 
knowledge of genetic factors associated with PC risk, in general, they have not been focused 
on clinically-significant disease nor directed towards ethnic groups at greatest risk of dying 
of PC, such as men of African ancestry.
Some of the initial discovery GWAS attempted to evaluate the associations between specific 
PC-risk SNPs and various aspects of disease aggressiveness (e.g., Gleason score). However, 
these studies were generally performed as post hoc analyses and involved heterogeneous 
definitions of disease aggressiveness. In addition, most of these analyses compared the 
frequency of genetic variants in men with high-grade disease to controls and men with low-
grade disease to controls. Only a relatively small proportion of GWAS in PC have been 
designed to evaluate the associations between genetic variants and clinically significant 
outcomes (e.g., disease aggressiveness) as their primary outcome measure. Xu et al. (2010) 
reported that the minor allele of single nucleotide polymorphism (SNP), rs4054823 on 
chromosome 17p12 was present at a significantly greater frequency in men with Gleason 
score ≥ 8 tumors and higher-stage disease (≥pT3b). Lin et al (2011) used a candidate gene 
approach to identify a panel of 5 SNPs associated with PC-specific mortality. However, 
other studies have not found robust associations with PC-specific mortality (Penney et al. 
2010). Other research groups have reported associations between individual SNPs on 
chromosomes 3p12, 8q24, 10q11, and 15q13 and the pathology features characteristic of 
aggressive PC (Ahn et al. 2011; Bensen et al. 2013; FitzGerald et al. 2011). A meta-analysis 
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aimed at determining whether genetic variants were associated with adverse pathology 
features reported that SNP rs11672691 showed associations with more aggressive tumors 
(Amin Al Olama et al. 2013). Additionally, results from other GWAS and linkage analyses 
have reported risk loci associated with aggressive disease amongst familial cases (Casey et 
al. 2006; Chang et al. 2005; Gudmundsson et al. 2008; Kirkland et al. 2010; Liu et al. 2011; 
Nam et al. 2011; Nurminen et al. 2011; Schaid et al. 2006; Schaid et al. 2007; Slager et al. 
2006; Stanford et al. 2006; Witte et al. 2000). In addition, Shui et al. reported that 8 SNPs 
were associated with lethal PC (Shui et al. 2014). The results of these studies are limited by 
the relatively small cohorts of PC patients of European ancestry studied, the heterogeneous 
definitions of aggressive disease used, reliance upon clinical (versus surgical) grading and 
staging of tumors, and lack of validation in diverse racial populations. Validation is essential 
to provide generalizability of results, especially since most of the genetic variants have only 
modest effects on disease risk and aggressiveness (OR 1.1–1.3).
The National Cancer Institute Prostate Cancer Genetics Working Group (GWG) was 
assembled to conduct a case-case association study of aggressive and non-aggressive PC 
(Catalona et al. 2011) using a panel of the then 36 validated SNPs associated with PC risk. 
In order to eliminate some of the variability in definitions of disease aggressiveness, only PC 
cases with complete information on disease aggressiveness and clinical follow-up were 
included in the analyses. Herein, we report our findings from a retrospective evaluation of 
more than 18,000 men with PC, including >8,000 men with aggressive disease, 5,000 men 
with non-aggressive disease, and >1800 African American men.
Methods and Materials
Study Samples
Nineteen PC research groups participated in this study and contributed clinical and genotype 
data (Supplemental Table 1). All institutions provided de-identified genotype and clinical 
information regarding pathologic tumor staging and grading to a central Data Coordinating 
Center (Northwestern University). The genotypes of 36 SNPs previously validated to be 
associated with PC risk were collected on a total of 25,674 cases with PC, including 23,278 
men of self-reported European ancestry, 2,129 of African ancestry, and 267 of unknown 
ancestry. This panel of SNPs was chosen for evaluation because at the time of the 2010 
NCI-SPORE GWG conference, it included the most comprehensive list of validated PC-risk 
SNPs. While information was collected on all 36 SNPs, there were varying numbers of 
SNPs available for analysis from each site (Supplemental Table 1). Details on the 
methodologies for genotyping at each individual institution are presented in Supplemental 
Table 2.
For men treated with surgery for PC, the pathology tumor grade and stage were used in the 
analysis. For men who underwent non-surgical treatments, the clinical stage and biopsy 
Gleason score were used. In addition, biochemical (PSA) evidence of tumor recurrence 
status and PC-specific mortality was documented for both cohorts of men. For the purposes 
of the present study, disease aggressiveness was defined in two ways: First, “aggressive 
disease” was indicated by PC-specific death, or distant metastasis, or lymph node 
involvement, or seminal vesicle invasion, or extracapsular tumor extension or Gleason score 
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≥8. “Non-aggressive” disease was defined strictly as Gleason ≤ 6 and clinically localized 
and organ-confined disease. For men who underwent radiation therapy, their clinical stage 
and grade was used to define organ-confined disease. “Intermediate disease” was defined as 
non-lethal with either Gleason 7 disease or biochemical recurrence. All cohorts required 
documentation of at least 3 years follow-up from the time of diagnosis and/or treatment, no 
high-risk pathology features, metastases or PC-specific mortality. A second overlapping 
definition of “aggressive disease” was based solely on the Gleason grade of the tumor. For 
this analysis, high-, intermediate- and low-grade tumors were defined by Gleason scores ≥8, 
7, and ≤6, respectively. Because there was incomplete data on the primary and secondary 
Gleason patterns, analyses that separated Gleason scores 3+4 and 4+3 could not be 
performed.
Exclusion Criteria
Men were excluded from the analysis if they did not have documentation of pathology 
Gleason score for men undergoing prostatectomy (n = 48, 0.2%), clinical Gleason score for 
men undergoing radiation therapy (147, 0.6%), data on PSA (n = 1481, 5.8%), staging (n = 
3408, 13.3%), and/or clinical follow-up information (n = 4878, 19.0%). Men were also 
excluded if they did not have documentation of either European or African-American 
ancestry (n = 267, 1.0%).
Statistical Analyses
Sensitivity analyses were performed comparing the genotypes of men fulfilling and those 
not meeting inclusion criteria. With the exception of one SNP, there were no differences 
between the included and excluded groups. However, the allele counts of SNP rs16902094 
on chromosome 8q24 were significantly different between excluded and included groups of 
men of European ancestry. This difference was eliminated after adjusting for length of 
clinical follow-up, i.e., when outcomes were compared among patients who had similar 
follow-up intervals.
Analyses were performed for the entire cohort and separately by self-reported race 
(European and African-American). The reference allele used for all analyses was defined by 
the allele previously associated with PC risk. We used logistic regression analysis to test for 
the association between the allele counts for each individual SNP and the presence of PC 
within the included cohorts. Alleles were coded in a log-additive manner, whereby the 
counts reflected the number of previously associated alleles. For some analyses, we 
stratified cases into those with aggressive, intermediate, or non-aggressive disease, and we 
treated these case groups as ordinal outcomes. The institutional site was documented to 
adjust for possible differences in genotyping methodology. As such, institutional site was 
included in the logistic regression model as a covariate using Northwestern University and 
the referent site
Multinomial logistic regression analysis was used to examine the association between allele 
counts (again for the previously-reported PC risk allele) and tumor aggressiveness as well as 
the potential association between allele counts and Gleason score. The Bonferroni correction 
was used to adjust for multiple testing.
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A total of 18,343 men (16,515 of European ancestry and 1,828 of African ancestry) met 
inclusion criteria. The clinical and pathology features of these men are shown (Table 1). Of 
the Caucasian men, 49.8%, 21.6% and 28.6% had aggressive, intermediate and non-
aggressive disease, respectively. Similarly, 39.4%, 34.2% and 26.4% men of African 
heritage were categorized as having aggressive, intermediate or non-aggressive disease. The 
numbers of men genotyped for each of the 36 SNPs are shown in Table 1 and Supplemental 
Table 3.
After adjusting for multiple testing, case-case logistic analyses comparing the genotypes of 
the entire cohort with aggressive, intermediate and non-aggressive disease showed that only 
the minor allele of rs2735839 (G) on chromosome 19q13 remained significantly (and 
inversely) associated with aggressive disease (p = 9.343 ×10−8; Table 2). Similarly, after 
correction for multiple testing, only the same SNP was significantly (and inversely) 
associated with the presence of aggressive disease in the European (p = 1.042 ×10−5) and 
African-American (p = 2.0 ×10−4; Table 2) cohorts
We also compared the allele count frequencies in men of European ancestry with high 
(Gleason score ≥8), intermediate (Gleason score =7), and low-grade disease (Gleason score 
=6). After correction for multiple testing, only the minor allele (G) of rs2735839 on 19q13 
remained significantly (and inversely) associated with high-grade disease in the entire cohort 
(p=1.389 ×10−8). Again, after correction for multiple testing, only the same SNP retained its 
significance within European (p=1.862 ×10−5) and African-American men (p=4.667×10−4; 
Table 3).
To determine whether the association between rs2735839 and high-risk and high-grade 
disease was due to a PSA screening bias, we performed subset analyses using various PSA 
cutoffs (Table 4). There was a significant and inverse association between rs2735839 and 
aggressive disease at nearly every PSA cutoff in both cohorts of European and African-
American men.
Discussion
Most previous studies of PC-risk alleles were not designed to identify genetic variants 
associated with aggressive disease because they were largely focused on men with a 
diagnosis of PC, irrespective of disease aggressiveness. In contrast, our study was aimed at 
identifying variants that are associated with PC aggressiveness rather than overall risk of PC 
(Helfand et al. 2010).
Previous studies have identified associations between SNPs within or near the PSA gene 
(KLK3) and high-grade tumors and adverse clinical outcomes (Bensen et al. 2013; Cramer et 
al. 2008; Gudmundsson et al. 2010; Lindstrom et al. 2011; Reinhardt et al. 2013; Slager et 
al. 2003; Xu et al. 2008). For example, using cohorts of European and Ashkenazi Jewish 
ancestry, two studies found that SNP rs2735839 in KLK3 was associated with PC-specific 
mortality (Gallagher et al. 2010; Pomerantz et al. 2011). In addition, the SNP rs2735839 on 
chromosome 19q13 within the KLK3 (PSA) gene has been previously evaluated in men of 
Helfand et al. Page 7













European ancestry for its association with clinico-pathologic features of prostate tumors 
(Bensen et al. 2013; He et al. 2014; Kader et al. 2009; Lindstrom et al. 2011; Nobata et al. 
2012; Pomerantz et al. 2011; Xu et al. 2008). Taken together, the G allele has been 
associated with PC risk and increased serum PSA levels, but also with significantly lower 
disease aggressiveness (Bensen et al. 2013). However, results have been inconsistent. In the 
present study of large cohorts of both European and African-American men, this SNP was 
present at significantly different frequencies amongst men with aggressive and high-grade 
disease compared to those with non-aggressive or low-grade disease. Since this genetic 
variant lies within the KLK3 gene, it is not surprising that variants within or around this gene 
could influence PC aggressiveness (Gudmundsson et al. 2010; Gudmundsson et al. 2009; He 
et al. 2014; Hsu et al. 2009; Kader et al. 2009; Lange et al. 2012; Pal et al. 2007; Penney et 
al. 2011; Schaid et al. 2007; Xu et al. 2008). Although the mechanism(s) of this association 
are unclear, it is possible that it may reflect, at least in part, a PSA detection bias (e.g., G 
allele of rs2735839 is associated with lower PSA expression and a delay in PC diagnosis). 
However, a PSA detection bias may not be sufficient to explain all of the current findings. 
For example, data from non-PSA-screened cohorts (Eeles et al. 2008a) and from men with 
low PSA values (Table 4) and functional studies (Lai et al. 2007) support the possibility of 
other potential roles for this locus, including PSA production, and the intrinsic risk of PC 
overall and of aggressive disease. Regardless, this SNP appears to have the potential ability 
to discriminate between aggressive and non-aggressive disease. Specifically, in men of 
European ancestry, this SNP discriminated between aggressive and non-aggressive disease 
within men with relatively low PSA values < 4ng/mL (Table 4). Because the clinical and 
pathology features were used to define the groups, we were not able to determine whether 
this allele adds independent prognostic information. Therefore, additional studies aimed at 
fully evaluating its clinical utility are needed.
Our results reveal similar findings with SNP rs2735839, whether we defined aggressive 
disease as high-grade disease (Gleason score ≥8) alone or a more comprehensive definition 
(PC-specific death, distant metastasis, lymph node involvement, seminal vesicle invasion, 
extracapsular tumor extension) (Tables 2 and 3). Taken together, our results suggest that 
Gleason score may be the driving force for determining the genetic basis of aggressive 
disease. While the mechanisms largely underlying their association with aggressive disease 
has largely remains elusive, it appears that PC-risk SNPs may influence gene expression 
including PSA(Chen et al. 2015; Jin et al. 2013).
It is well established that men of African descent are at significantly increased risk of PC, 
with a greater proportion being diagnosed at an earlier age with aggressive disease (Moul 
2000; Zeliadt et al. 2003). Specifically, African- American men have a 50% higher 
incidence and more than a 240% higher mortality rate of PC than Caucasian men (Hsing and 
Chokkalingam 2006) (Taksler et al. 2012). Unfortunately, the majority of genetic studies 
have not included large cohorts of African-American men. The present study is strengthened 
by the fact that it highlights both similarities and differences between African-American and 
European men. For example, there were many more SNPs that were marginally associated 
with high-risk and high–grade disease in the European compared to African-American men 
(Tables 2 and 3). As stated above, this is likely related to the mechanisms of their initial 
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discovery in Caucasian cohorts (Han et al. 2014). Other nearby or related SNPs may also be 
associated with aggressive disease in African-Americans, and more studies within this 
population are needed. Interestingly, both racial populations showed an association between 
the aggressive phenotype and the minor allele of rs2735839 (G). This suggests a robustness 
of the association in other racial populations as well as a common genetic mechanism for PC 
aggressiveness.
Our study has several strengths, including its involvement of large cohorts with aggressive 
prostate tumors. This allowed the identification of PC-risk SNPs with at least marginally 
significant associations with aggressive disease. These small relative risks of aggressive 
disease are somewhat expected given similar associations between these SNPs and overall 
disease risk. However, based upon the fact that these SNPs are common within the general 
population and have a low penetrance, we cannot exclude the possibility of false positive 
results. Additionally, we used a widely validated subset of PC risk variants in the present 
study. This relatively limited subset of 36 SNPs allowed us to evaluate more fully the SNPs 
in a new context without having the same statistical constraints as many GWAS studies that 
involve millions of other SNPs. However, this same subset also limited the scope of our 
results, as it did not permit the identification of other more recently validated risk SNPs or 
novel genetic variations that may better predict PC aggressiveness. Furthermore, we did not 
have genotype data on all 36 SNPs in all patients included in the study. This limited the 
statistical power. Therefore, future case-case GWAS involving large cohorts of men with 
complete genotype data are needed. In addition, future complementary case-control studies 
evaluating these same SNPs would be needed to better define the direction and magnitude of 
the associations with aggressive disease. Additionally, although our study population 
represents one of the largest cohorts of men with African-American ancestry, the statistical 
power remains limited, and the results require replication in larger, independent datasets. 
Furthermore, it should be noted that there may have been a selection bias present since the 
proportion of African-American men with aggressive disease included in the cohort was 
significantly less than among European-Americans. Furthermore, our results may have been 
confounded by the fact that race was self-reported and lacked associated genetic information 
on ancestry. While our results are limited by the definition of disease aggressiveness used, it 
emphasizes the need for replication, as the majority of prior aggressiveness loci have failed 
to be replicated.
In summary, we provide further evidence that a single PC risk SNP (rs2735839) on 
chromosome 19q13 may be associated with high-risk and high-grade PC. Future prospective 
designed, case-case GWAS should be performed to identify additional SNPs associated with 
PC aggressiveness
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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